Currently, suboptimal mental health, emotional disorders and traumatic stress disorders are rising year by year, while traditional psychological interventions suffer from homogenization and insufficient targeting. Based on neuroplasticity and the Expressive Therapies Continuum theory, this study systematically analyzes pathological characteristics and repair logic of core brain regions including the prefrontal cortex, amygdala and hippocampus, and compares differentiated neural regulatory effects of four categories of art forms: painting, music, handcraft and passive aesthetic appreciation. The study identifies brain region activation rules and intervention advantages corresponding to each art modality, and distinguishes the varied functions of active creation and passive aesthetic appreciation in emotion regulation, cognitive remodeling and traumatic memory repair. This study makes up for the deficiency that existing research stresses practical effects yet lacks analysis of differentiated action mechanisms. It establishes an intervention framework matching art forms, cerebral regulatory characteristics and crowd demands, and promotes art therapy from experience-based implementation toward more targeted scientific intervention. Future research can adopt multimodal neuroimaging experiments to further quantify intervention thresholds of different art modalities and long-term cerebral functional remodeling rules, so as to improve the precise art therapy system.

Upper-limb amputation seriously affects a person's daily life. Traditional commercial myoelectric prostheses have only 2-6 degrees of freedom (DOFs) and are not yet capable of fine-motor manipulation. This paper reviews representative progress from 2014 to the first half of 2026 in three main directions: mechanism design and actuation, intelligent control and intention decoding, and sensory feedback and closed-loop interaction. The reviewed studies show that advanced mechanical configurations can add more active DOFs while reducing weight; deep learning decoding and shared semi-autonomous control can improve the accuracy and ease of control; and bidirectional neural interfaces, such as the e-OPRA system, have demonstrated the feasibility of closed-loop interaction. The analysis indicates that increasing the effective DOFs of prostheses requires the systematic integration of mechanisms, control and sensory feedback, rather than simply adding more joints.

Oral coenzyme Q10 (CoQ10) supplements are widely used to support mitochondrial function and antioxidant defenses. Although studies have reported potential benefits in selected cardiovascular and neurological conditions, the mechanisms governing absorption and delivery to target tissues remain incompletely understood. This review examines the transport of orally administered CoQ10 from the gastrointestinal tract to the circulation, its distribution among organs, and its potential passage across the blood–brain barrier. It considers the redox forms of CoQ10 during intestinal absorption, the effects of supplement formulation and individual physiology on bioavailability, and the role of circulating lipoproteins in transport. It also discusses experimental models used to investigate tissue uptake and candidate mechanisms of blood–brain barrier transport. Finally, the review identifies questions concerning cellular uptake and intracellular delivery to mitochondria. Distinguishing increased plasma concentrations from effective delivery to tissues and subcellular sites is essential for interpreting supplementation studies. A clearer understanding of these processes could guide the design of formulations and experiments that evaluate both target-tissue exposure and functional responses.

EGFR-TKIs have significantly improved the survival outcomes of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, substantial heterogeneity in treatment efficacy exists among individuals, and conventional single-gene testing has limitations in guiding therapeutic decision-making. This systematic review focuses on the effects of driver gene co-mutations on the prognosis of targeted therapy in EGFR-mutant NSCLC and explores their value in clinical translation. Literature published from 2022 to 2026 concerning co-mutations and prognosis of targeted therapy in EGFR-mutant NSCLC was systematically retrieved from the PubMed database for summarization and analysis. This review found that TP53 is the most prevalent co-mutated gene in EGFR-mutant NSCLC and is strongly associated with poor prognosis under TKI monotherapy. Phase III clinical trials have confirmed that TKI combined with chemotherapy significantly prolongs median progression-free survival compared with TKI monotherapy among patients with EGFR mutations accompanied by tumor suppressor gene co-mutations. NGS multi-gene panels serve as the technical foundation for comprehensive co-mutation assessment. In summary, driver gene co-mutations play a critical role in prognostic stratification for EGFR-mutant NSCLC treatment. Taking co-mutation status into account helps identify high-risk patients who may benefit from intensified treatment, supporting more precise and individualized targeted therapy.

With an aging population and changes in environmental and lifestyle factors, the incidence of hematologic malignancies has been increasing worldwide. Diseases such as leukemia, lymphoma, and multiple myeloma are often characterized by rapid progression and high relapse rates, posing a serious threat to human health. Conventional treatment modalities, including chemotherapy, radiotherapy, and transplantation of hematopoietic stem cells, have demonstrated limited efficacy among individuals with relapsed or refractory hematologic malignancies. Drug resistance, low remission rates, and poor prognosis remain major clinical concerns, underscoring the pressing demand for innovative therapeutic approaches capable of addressing the limitations of current treatments. Chimeric antigen receptor T-cell (CAR T-cell) therapy is widely regarded as a significant advancement in the field of cancer immunotherapy. Owing to its precise targeting and potent antitumor activity, CAR T-cell therapy has provided a novel treatment option for individuals affected by relapsed or refractory hematologic malignancies. Based on relevant literature review and inductive analysis, this review offers a comprehensive overview of recent progress regarding the clinical use of CAR T-cell therapy for a range of hematologic malignancies. It focuses on the major challenges associated with clinical application, particularly cytokine release syndrome, tumor immune evasion, and high treatment costs. In addition, current technological improvements and clinical optimization strategies are discussed, and future development trends are explored. Existing evidence indicates that, compared with conventional treatment modalities, CAR T-cell therapy provides clinically meaningful benefits for individuals with relapsed or refractory hematologic malignancies. It can improve remission rates and clinical outcomes and therefore has considerable clinical value. However, several limitations remain, including the risk of serious adverse events, tumor immune evasion, and high costs, all of which substantially hinder its clinical translation and widespread application.